Thanks, Olivia. Good afternoon, everyone.
December, and we in the that of monitoring IMerge first committee independent III held trial. As our Chip Also, the Phase modification. meeting without IDMC have the now recommended enrollment XX% trial continue in the was achieved mentioned, data
return boosting the year over last hopefully enrollment months. to we activities normal expect as several as to operations COVID cases We decline next to become more started the and effective clinical begin
personnel of of the As with benefits help will last sites clinical science result, to liaisons believe engaged the participating site IMerge greater were and clinical year and in with frequency to easily in able more beginning we a interact patients to alert III. Phase be the potential
our In will addition, help patient media we believe social recruitment. drive campaign
the sites additional approximately expect approximately open, XX the number Over total will all bringing few be to next of months, this trial for of the IMerge in we XXX. sites
should and trials. IMerge clinical the approved this very on the as encouraging. patients, and from more on vaccinations or expand the of from low-risk differentiate proceed, enrollment become kind to continue homes number leaving again, MDS, of to These Phase data mentioned mature II cases Of Chip comfortable in come decline Earlier their investigational severity like more briefly. COVID participate in clinical our to which course, best data in currently boost we would And trial other to are treatments. I imetelstat call,
Foremost, its independent. remarkable transfusion imetelstat achieves durability for
year. of of a patients secondary In XX which were weeks, were the to X-week patients of that for endpoint addition XX% transfusion independent, of those for imetelstat the the XX% Furthermore, a free XX% patients was transfusion transfusion achieved primary endpoint. over free key
data and very population our results That for duration seen patient patients. patient results treatment to were be duration results [indiscernible] of in We from come MDS the these available III. These X imetelstat obtained Phase of in independence very similar which months a recent transfusion highly of transfusion competitive months. of compares IMerge as the burden. like the differentiated reported. XX reported was then RS- well believe I'd favorably a also similar heavy both to as most have for also RS+ independence a population. that will median emphasize We And we've with lower-risk transfusion are baseline very median from
was in Chip to also months, MS These months. OS were OS with the best the matched medical Phase Moving in his survival median relapsed/refractory compared The patients of imetelstat observing our on to the patients, are treated overall literature. mentioned compares median therapy to to months in median of favorably and XX the myelofibrosis. XX earlier the very treated XX trial, data of XX real-world In II the favorably that remarks, OS who carefully available analysis IMbark. IMbark they
patients clinical correlated symptom bone to been than overall IMpactMF addition after and and survival, survival. in improvement IMbark opened volume important we with expected. improvement, In experienced which clinical These other on data reduction was in earlier improvement. have fibrosis the to screen conferring benefits, the Based including X marrow December, FDA, overall in these benefits quarter
are XXXX. analysis patients. patients. we As the reach which media to with the compete dynamics in late-stage Phase with of III. sites; clinical the differentiating social the the assumptions, XXXX IMpactMF. primary other internal will number enrollment that clinical in mentioned, planning IMerge liaisons; will a be for that IMerge expect is trial employed full that today's for Under affecting a using key And survival analysis science and utilizing engaging only this affecting in and start-up MF boosting compared Phase a feature IMpactMF more endpoint, also and enrollment We're also we've final overall similar And expanding population first drugs III those in XXXX. occur enrollment campaign. to III countries in trials as in in current in in The other IMpactMF we Phase seen may same addition, of enrollment include MS of strategies numerous have IMpactMF IMpactMF, and These development
me expand occur XXXX Let interim overall of is the The time survival. on bit line. reason analysis study this primary the a because could endpoint that in
clinical stem imetelstat cells reductions remarkable drug kills activity of In responsible MMF. psychogenetic trials molecular depletion could end were MDS dose-dependent improvement imetelstat noting as of In reaching on of MF the of providing of Telomeres. the a very that directly with indicates level events. along throughout disease-modifying analysis imetelstat enrollment possible of bone course my remarks in that disease-modifying their action of of molecular like observed Telomeres provide correlations. with transfusion our of activity durable IMbark, key be disease-modifying magnitude also events independence that It These data the saw the unique malignant and mutations I'd targeting the that overall further inhibition to the As a believe key reporting reductions events seen transfusion period. driver is the survival in this action mutations of maybe trial, mechanism driver MF the and data the low-risk strong surviving of fibrosis. imetelstat. a the benefit we're test complete. We patients, in for MDS important of imetelstat. alters before data IMbark in independence, and evidence linked that significant we've burden marrow will improvement evidence Phase Highlights accrue a These to the conduct certain well of of MDS up II mutation the evidence progenitor in by strengthening will of strong a were clinical the of analysis low-risk in of occur we based at with imetelstat's abnormalities, overall number to improved correlated low-risk required data and and molecular timing for of and benefit observed the by in correlated is interim These as M&A. result, also mechanism and number activity that interim enrollment we've
will the There's the have cannot potential like now we III confidence result, to current IMerge in I'd Chip hear line? have and a call we with your IMpactMF. MDS hand that to marketplaces. back both Phase success MMF something to you. review Chip? As we further Chip,
